Literature DB >> 4210892

Preliminary clinical experience with ticarcillin (BRL 2288) in 101 patients treated for severe respiratory infections.

A Pines, G Khaja, H Raafat, K S Sreedharan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4210892     DOI: 10.1159/000221789

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


× No keyword cloud information.
  4 in total

1.  [Therapy with cefotaxime-cefotaxime/ticarcillin for bronchopulmonary infections in patients under intensive care. (author's transl)].

Authors:  C D Schwigon
Journal:  Infection       Date:  1982       Impact factor: 3.553

2.  Comparative activity in vitro of ticarcillin, BL-P1654, and carbenicillin.

Authors:  T C Eickhoff; J M Ehret
Journal:  Antimicrob Agents Chemother       Date:  1976-08       Impact factor: 5.191

3.  [Current chemotherapy of infections caused by Pseudomonas aeruginosa (author's transl)].

Authors:  A Bauernfeind; C Petermüller; M Dietzel
Journal:  Infection       Date:  1979       Impact factor: 3.553

Review 4.  Ticarcillin: a review of its pharmacological properties and therapeutic efficacy.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-11       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.